Navigation Links
Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015
Date:12/15/2009

NEW YORK, Dec. 15 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015

http://www.reportlinker.com/p0167308/Systemic-Lupus-Erythematosus---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015.html

Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015

Summary

GlobalData, the industry analysis specialist's new report, "Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global systemic lupus erythematosus market. The report identifies the key trends shaping and driving the global systemic lupus erythematosus market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global systemic lupus erythematosus sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- Annualized global systemic lupus erythematosus market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.

- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include T and B cell modulators, Immunomodulators, Hormonal Agents, phosphodiesterase type 4 inhibitor, Anti Alpha INF, Interleukin inhibitors and anti CD antigens.

- Analysis of the current and future market competition in the global systemic lupus erythematosus market. Key market players covered are F. Hoffmann-La Roche Ltd (Genentech) , MedImmune, Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, UCB S.A, Amgen and Biogen Idec.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with systemic lupus erythematosus.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global systemic lupus erythematosus market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global systemic lupus erythematosus market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global systemic lupus erythematosus market landscape? - Identify, understand and capitalize.

Table of Contents

1 Systemic Lupus Erythematosus Market: Executive Summary

1.1 The Systemic Lupus Erythematosus Market is Forecast to Show Positive Growth until 2015

1.2 Major Companies Focusing on SLE Drug Development Landscape

1.3 Strong Pipeline with First-in Class Candidates Raise Hope to SLE Treatment Paradigm

1.4 High Unmet Need Continues to Remain Unaddressed

2 Table Of Contents

2.1 List of Tables

2.2 List of Figures

3 Global Systemic Lupus Erythematosus Market: Market Characterization

3.1 Overview

3.2 Systemic Lupus Erythematosus Market Size

3.3 Systemic Lupus Erythematosus Market Forecast and CAGR

3.4 Drivers and Barriers for Systemic Lupus Erythematosus Market

3.4.1 Drivers for Systemic Lupus Erythematosus Market

3.4.2 Barriers for Systemic Lupus Erythematosus Market

3.5 Opportunity and Unmet Need

3.6 Key Takeaway

4 Global Systemic Lupus Erythematosus Market : Competitive Assessment

4.1 Overview

4.2 Strategic Competitor Assessment

4.3 Major Therapies and Off-Label Marketed Products in Systemic Lupus Erythematosus Market

4.3.1 Non-steroidal anti-inflammatory drugs (NSAIDs)

4.3.1.1 Overview

4.3.1.2 Aspirin

4.3.2 Anti-Malarials

4.3.2.1 Overview

4.3.2.2 Plaquenil (Hydroxychloroquine)

4.3.3 Corticosteroids

4.3.3.1 Overview

4.3.3.2 Prednisone

4.3.4 Immunosuppressant or Cytotoxic Drugs

4.3.4.1 Overview

4.3.4.2 CellCept (Mycophenolate Mofetil)

4.3.4.3 Rituxan (rituximab)

4.4 Key Takeaway

5 Global Systemic Lupus Erythematosus Market : Pipeline Assessment

5.1 Overview

5.2 Strategic Pipeline Assessment

5.2.1 Technology Trends Analytic Framework

5.3 Systemic Lupus Erythematosus Therapeutics -Promising Drugs under Clinical Development

5.4 Molecule Profile for Promising Drugs under Clinical Development

5.4.1 BENLYSTA (belimumab)

5.4.1.1 Overview

5.4.1.2 Efficacy

5.4.1.3 Safety

5.4.1.4 Clinical Study Details

5.4.2 Atacicept

5.4.2.1 Overview

5.4.2.2 Efficacy

5.4.2.3 Safety

5.4.2.4 Clinical Study Details

5.4.3 Ocrelizumab (Humanized Anti-CD20 mAb)

5.4.3.1 Overview

5.4.3.2 Efficacy

5.4.3.3 Safety

5.4.3.4 Clinical Study Details

5.4.4 Prestara(TM)

5.4.4.1 Overview

5.4.4.2 Efficacy

5.4.4.3 Safety

5.4.4.4 Clinical Study Details

5.4.5 Epratuzumab

5.4.5.1 Overview

5.4.5.2 Efficacy

5.4.5.3 Safety

5.4.5.4 Clinical Study Details

5.4.6 Lupuzor(TM)

5.4.6.1 Overview

5.4.6.2 Efficacy

5.4.6.3 Safety

5.4.6.4 Clinical Study Details

5.5 Systemic Lupus Erythematosus Therapeutics Market - Clinical Pipeline by Mechanism of Action

5.6 Systemic Lupus Erythematosus - Pipeline by Clinical Phases of Development

5.6.1 Systemic Lupus Erythematosus Therapeutics - Phase III Clinical Pipeline

5.6.2 Systemic Lupus Erythematosus Therapeutics - Phase II Clinical Pipeline

5.6.3 Systemic Lupus Erythematosus Therapeutics - Phase I Clinical Pipeline

5.6.4 Systemic Lupus Erythematosus Therapeutics - Preclinical Pipeline

5.6.5 Systemic Lupus Erythematosus Therapeutics - Discovery Pipeline

5.7 Discontinued / Suspended Drugs for Systemic Lupus Erythematosus

5.8 Key Takeaway

6 Global Systemic Lupus Erythematosus Market : Implications for Future Market Competition

7 Global Systemic Lupus Erythematosus Market : Future Players in SLE Market

7.1 Introduction

7.2 Biogen Idec

7.2.1 Overview

7.2.2 Autoimmune Portfolio

7.2.2.1 Marketed Products

7.2.2.2 Pipeline Products

7.2.3 Systemic Lupus Erythematosus Product Portfolio

7.2.3.1 Ocrelizumab (RG1594)

7.2.3.2 Anti-CD40CL

7.3 MedImmune

7.3.1 Overview

7.3.2 Autoimmune Portfolio

7.3.2.1 Marketed Products

7.3.2.2 Pipeline Products

7.3.3 Autoimmune Product Portfolio

7.3.3.1 MEDI-545 (MDX-1103)

7.3.3.2 Anti-ILT-7

7.4 F. Hoffmann-La Roche Ltd (Genentech, Inc)

7.4.1 Overview

7.4.2 Autoimmune Portfolio

7.4.2.1 Marketed Products

7.4.2.2 Pipeline Products

7.4.3 Systemic Lupus Erythematosus Product Portfolio

7.4.3.1 RG7415 (rontalizumab)

7.5 Amgen Inc

7.5.1 Overview

7.5.2 Autoimmune Portfolio

7.5.2.1 Marketed Products

7.5.2.2 Pipeline Products

7.5.3 Systemic Lupus Erythematosus Product Portfolio

7.5.3.1 AMG 811

7.5.3.2 AMG 557

7.6 Bristol-Myers Squibb

7.6.1 Overview

7.6.2 Autoimmune Portfolio

7.6.2.1 Marketed Products

7.6.2.2 Pipeline Products

7.6.3 Systemic Lupus Erythematosus Product Portfolio

7.6.3.1 Abatacept

7.7 UCB S.A

7.7.1 Overview

7.7.2 Autoimmune Portfolio

7.7.2.1 Marketed Products

7.7.2.2 Pipeline Products

7.7.3 Systemic Lupus Erythematosus Product Portfolio

7.7.3.1 Epratuzumab

7.8 GlaxoSmithKline plc

7.8.1 Overview

7.8.2 Autoimmune Portfolio

7.8.2.1 Marketed Products

7.8.2.2 Pipeline Products

7.8.3 Systemic Lupus Erythematosus Product Portfolio

7.8.3.1 Belimumab (BENLYSTA)

7.8.3.2 Prestara

8 Global Systemic Lupus Erythematosus Market : Appendix

8.1 Definitions

8.2 Acronyms

8.3 Research Methodology

8.3.1 Coverage

8.3.2 Secondary Research

8.3.3 Forecasting

8.3.3.1 Epidemiology-based Forecasting

8.3.4 Primary Research

8.3.5 Expert Panel validation

8.4 Contact Us

8.5 Disclaimer

8.6 Sources

List of Tables

Table 1: Global SLE Therapeutics Market, Revenue ($m), 2000-2008

Table 2: Global SLE Therapeutics Market, Revenue ($m), 2008-2015

Table 3: Systemic Lupus Erythematosus Therapeutics - Most Promising Drugs Under Clinical Development, 2009

Table 4: Systemic Lupus Erythematosus Therapeutics - Phase III Clinical Pipeline, 2009

Table 5: Systemic Lupus Erythematosus Therapeutics - Phase II Clinical Pipeline, 2009

Table 6: Systemic Lupus Erythematosus Therapeutics - Phase I Clinical Pipeline, 2009

Table 7: Systemic Lupus Erythematosus Therapeutics - Preclinical Pipeline, 2009

Table 8: Systemic Lupus Erythematosus Therapeutics - Discovery Pipeline, 2009

Table 9: List of Discontinued/Suspended Drugs for Systemic Lupus Erythematosus, 2009

Table 10: Biogen Idec - Autoimmune Marketed Products, 2009

Table 11: Biogen Idec - Autoimmune Pipeline Products, 2009

Table 12: MedImmune - Autoimmune Pipeline Products, 2009

Table 13: F. Hoffmann-La Roche Ltd - Autoimmune Marketed Products, 2009

Table 14: F. Hoffmann-La Roche Ltd - Autoimmune Pipeline Products, 2009

Table 15: Amgen Inc - Autoimmune Marketed Products, 2009

Table 16: Amgen Inc - Autoimmune Pipeline Products, 2009

Table 17: Bristol-Myers Squibb - Autoimmune Marketed Products, 2009

Table 18: Bristol-Myers Squibb - Autoimmune Pipeline Products, 2009

Table 19: UCB S.A - Autoimmune Marketed Products, 2009

Table 20: UCB S.A - Autoimmune Pipeline Products, 2009

Table 21: GlaxoSmithKline plc- Autoimmune Marketed Products, 2009

Table 22: GlaxoSmithKline plc - Autoimmune Pipeline Products, 2009

List of Figures

Figure 1: Global SLE Therapeutics Market Revenue ($m) 2000-2015

Figure 2: Opportunity and Unmet Need, 2009

Figure 3: Strategic Competitor Assessment of the Major Off-Label Products in SLE, 2009

Figure 4: Technology Trends Analytic Framework of the SLE Pipeline, 2009

Figure 5: Technology Trends Analytic Framework of the SLE Pipeline- Description, 2009

Figure 6: SLE Market- Clinical Pipeline by Mechanism of Action, 2009

Figure 7: Systemic Lupus Erythematosus Pipeline by Phase of Clinical Development, 2009

Figure 8: Implications for Future Market Competition in the SLE Market, 2009

Figure 9: Systemic Lupus Erythematosus Market - Clinical Pipeline by Company, 2009

Figure 10: GlobalData Methodology

Figure 11: GlobalData Market Forecasting Model

Companies mentioned

GlaxoSmithKline Plc, Human Genome Sciences, F. Hoffmann-La Roche Ltd, Genentech, MedImmune, Bristol-Myers Squibb , UCB S.A, Amgen, Biogen Idec, ImmuPharma, Merck Serono, ZymoGenetics, Genelabs Technologies, ImmuPharma, Cephalon Inc,

To order this report:

Pharmaceutical Industry: Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015

More Market Research Report


    Contact Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
2. Reportlinker Adds Top Ten Worlds Leading Orthopedics Companies
3. Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
4. Reportlinker Adds Medical Fiber Optics - A World Market Analysis
5. Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities
6. Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis
7. Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide
8. Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009
9. Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
10. Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis
11. Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... IRVINE, Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: ... quarter ended December 31, 2015. The Company also filed its ... fiscal year 2016 with the Securities and Exchange Commission today. ... December 31, 2015 --> --> ... 2015 increased $2.6 million, or 95%, to $5.4 million from ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 , ... new health technologies, announced today " 10 Year Global ... health tech over the past ten years.   ... a decade, Health 2.0 has served as the preeminent ... connected with thousands of technologies, companies, innovators, and patient-activists ...
(Date:2/11/2016)... , Feb. 11, 2016  AfterPill.com is reporting that ... alcohol abstinence for all women who are at risk ... U.S. each year and raises the risks of unprotected ... --> According to the Guttmacher Institute, there ... women of child-bearing age, who have sex without the ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 2016 , ... Hidden Cypress in Sun City is the place to be on March 3rd ... Frederick Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. ... special pricing on offers. In addition, prizes will be given away and light refreshments will ...
(Date:2/13/2016)... ... ... individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased their ... delved into this niche allowing those giving up their beloved pasta a chance to ... of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio that ...
(Date:2/13/2016)... Tennessee (PRWEB) , ... February 13, 2016 , ... ... the Infusion Nurses Society (INS) states that vein visualization technology should be used ... by healthcare facilities around the world, the INS Standards mandate the use of ...
(Date:2/13/2016)... ... , ... In the early or “honeymoon” stage of a relationship, couples strive ... their way to be romantic, and may exaggerate a strength or two in an ... profile. , A recent study from Queendom.com , however, suggests that new ...
(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
Breaking Medicine News(10 mins):